Q1 2022 Results

Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health PluvictoⓇ- Radioligand therapy target PSMA Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) NCT04689828 PSMAfore (CAAA617B12302) Metastatic castration-resistant prostate cancer, pre-taxane Phase 3 450 Radiographic Progression Free Survival (rPFS) Arm 1: Participants will receive 7.4 GBq (200 mCi) +/- 10% lutetium (177Lu) vipivotide tetraxetan once every 6 weeks for 6 cycles. Best supportive care, including ADT may be used Arm 2: For participants randomized to the ARDT arm, the change of ARDT treatment will be administered per the physician's orders. Best supportive care, including ADT may be used mCRPC patients that were previously treated with an alternate ARDT and not exposed to a taxane-containing regimen in the CRPC or MHSPC settings Primary Analysis: 2022 Final Analysis: 2025 NCT04720157 PSMAddition (CAAA617C12301) Metastatic hormone sensitive prostate cancer Phase 3 1126 Radiographic Progression Free Survival (rPFS) Arm 1: lutetium (177Lu) vipivotide tetraxetan Participant will receive 7.4 GBq (+/- 10%) lutetium (177Lu) vipivotide tetraxetan, once every 6 weeks (+/- 1 week) for a planned 6 cycles, in addition to the Standard of Care (SOC); ARDT +ADT is considered as SOC and treatment will be administered per the physician's order Arm 2: For participants randomized to Standard of Care arm, ARDT +ADT is considered as SOC and treatment will be administered per the physician's order Patients with metastatic Hormone Sensitive Prostate Cancer (mHSPC) Primary Analysis: 2024 Publication 94 Investor Relations | Q1 2022 Results TBD TBD 1 NOVARTIS | Reimagining Medicine

View entire presentation